MK-2010 / LaNova Medicines Limited, Merck (MSD) - LARVOL DELTA

Study of LM-299 in Subjects Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=108 | Recruiting | Sponsor: LaNova Medicines Limited | N=230 ➔ 108

Enrollment change • Monotherapy • Oncology • Solid Tumor

Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. (Merck (MSD) Press Release) - "Merck...and LaNova Medicines Ltd. (LaNova)...today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova...Under the agreement, LaNova has granted Merck an exclusive global license to develop, manufacture and commercialize LM-299. LaNova will receive an upfront payment of $588 million. LaNova is also eligible to receive up to $2.7 billion in milestone payments associated with the technology transfer, development, regulatory approval and commercialization of LM-299 across multiple indications."

Licensing / partnership • Oncology • Solid Tumor

LaNova Medicines Announces…Completion of $42 Million Series C1 Financing (PRNewswire) - "LaNova has recently initiated its Series C2 financing round. Proceeds will be primarily used to advance the clinical development of the Company's pipeline, including lead candidates: LM-302 (anti-CLDN 18.2 ADC): ongoing Phase III registrational clinical trial in China for gastric cancers, making it one of the top three candidates globally in terms of development progress for this target; US Phase II trial expected to start in H2 2025; LM-108 (anti-CCR8 mAb): ongoing Phase II clinical trials in China for multiple solid tumors, making it one of the top three most advanced projects worldwide targeting CCR8; US Phase II trial expected to start in H2 2024; LM-299 (anti-PD-1/VEGF BsAb): Phase I clinical trial in China is currently enrolling patients for advanced solid tumors."

Financing • New P2 trial • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

LaNova Medicines Announces Initiation of Phase 1 Clinical Trial of Anti-PD-1/VEGF Bispecific Antibody LM-299… (PRNewswire) - "LaNova Medicines Limited...announced the initiation of its Phase 1 clinical trial of LM-299, an anti-PD-1/VEGF BsAb, in China for advanced solid tumors...LaNova is planning to initiate an additional Phase 1 clinical trial in the US and expects to submit an IND in the second half of 2024."

IND • New P1 trial • Oncology • Solid Tumor

Study of LM-299 in Subjects Advanced Malignant Tumors (clinicaltrials.gov) - P1/2 | N=230 | Recruiting | Sponsor: LaNova Medicines Limited

Combination therapy • Metastases • New P1/2 trial • Oncology • Solid Tumor